Golimumab Biosimilar – Anti-TNFA, TNF alpha mAb – Research Grade

Description of Golimumab Biosimilar - Anti-TNFA, TNF alpha mAb - Research Grade

General information on Anti-TNFA/TNF alpha(Homo sapiens) (Golimumab) Monoclonal Antibody

Golimumab is a human IgG1 alpha monoclonal antibody, developped from genetically engineered mice immunized with human TNFalpha. Golimumab binds to and inhibits soluble and transmembrane human TNFalpha. Elevated TNFalpha is related to chronic inflammation. Therefore, golimumab can be used in adults,for the treatment of active rheumatoid arthritis (RA), active psoriatic arthritis ( PsA), active ankylosing spondylitis (AS), ulcerative colitis (UC). In the United States and Canada, golimumab is sold under the Simponi® brand. The FDA label includes a black box that warns of serious infections and malignant tumors.

Golimumab Biosimilar - Anti-TNFA, TNF alpha mAb binds to Human TNFa/TNF-alpha in indirect ELISA Assay

Immobilized Human TNFa Recombinant Protein (cat. No. PX-P3058) at 0.5µg/mL (100µL/well) can bind Golimumab Biosimilar - Anti-TNFA, TNF alpha mAb (cat. No. PX-TA1129) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 3.028M.

Golimumab Biosimilar - Anti-TNFA, TNF alpha mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.